Viatris Inc (VTRS)

13.76
-0.43(-3.03%)
Pre Market
13.99
+0.23(+1.67%)
- Real-time Data
  • Volume:
    10,168,548
  • Bid/Ask:
    13.70/14.00
  • Day's Range:
    13.68 - 14.18

VTRS Overview

Prev. Close
13.76
Day's Range
13.68-14.18
Revenue
13.76B
Open
14.01
52 wk Range
12.95-18.86
EPS
-1.5
Volume
10,168,548
Market Cap
16.63B
Dividend (Yield)
0.44
(3.10%)
Average Vol. (3m)
7,819,702
P/E Ratio
-
Beta
1.48
1-Year Change
-15.69%
Shares Outstanding
1,208,655,503
Next Earnings Date
Aug 09, 2021
What is your sentiment on Viatris Inc?
or
Market is currently closed. Voting is open during market hours.

Viatris Inc News

  • Viatris: Buy or Sell?
    • ByStockNews-

    Viatris (VTRS) is a pharmaceutical company that sells a variety of different drugs. The company plans to offer its first ever dividend and is currently trading at a very low...

Viatris Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Viatris Inc Company Profile

Viatris Inc Company Profile

Employees
40000

Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.